

A DELETION MUTATION IN *nfxB* OF *IN VITRO*-INDUCED MOXIFLOXACIN-RESISTANT *PSEUDOMONAS AERUGINOSA* CONFERS MULTIDRUG RESISTANCE

VAN CHI THAI¹, HOANG VY PHAM¹, DUC NHAT MINH NGUYEN¹,
PETER LAMBERT² and THI THU HOAI NGUYEN^{1*}

¹School of Biotechnology, International University, VNU-HCMC, Ho Chi Minh City, Vietnam

²School of Life and Health Sciences, Aston University, Birmingham, UK

(Received: 8 August 2016; accepted: 22 November 2016)

The modulation of efflux pump functions under fluoroquinolone (FQ) exposure is of great concern as it could result in occurrence of multidrug-resistant (MDR) bacterial strains. In this study, MDR mechanism in *Pseudomonas aeruginosa* induced via moxifloxacin (MOX) pressure was investigated. After serial MOX [concentration of $0.5 \times$ the minimum inhibitory concentration (MIC)] exposure, the fully susceptible *P. aeruginosa* ATCC 9027 strain has increased its MIC not only toward MOX ($1 \rightarrow 128$ mg/L) but also to other antibiotics. Furthermore, this MOX-exposed strain did not revert to antibiotic-sensitive phenotype when being cultured in antibiotic-free medium for 12 days. No mutation was observed for FQ-target (*gyrA* and *parC*) or most investigated efflux regulatory genes (*mexT*, *mexR*, and *nalC*) except *nfxB* in which a 100-bp deletion was found. This associated with the elevated expression of multidrug efflux pump operon (*mexCD-oprJ*) which could directly result in MDR phenotype.

Keywords: moxifloxacin, multidrug resistance, *P. aeruginosa*, *nfxB*

Introduction

Pseudomonas aeruginosa is regarded as one of the major causes of nosocomial infections worldwide [1]. Treatment of *P. aeruginosa* infections has now become more challenging due to its remarkable propensity to rapidly acquire resistance to a wide range of antibacterial agents [2].

Fluoroquinolone (FQ) class of antimicrobial agents has been increasingly and extensively used for hospitalized as well as community patients since the late

*Corresponding author; E-mail: ntthoai@hcmiu.edu.vn

1980s due to its potent and broad-spectrum activity against a wide range of Gram-positive and Gram-negative pathogens [3]. In many countries, FQs are the only commonly available oral therapy to treat *P. aeruginosa* infections [4, 5]. FQ resistance can be considered as one of the consequences to widespread FQ consumption together with multidrug resistance (MDR), it has arisen at an alarming rate among *P. aeruginosa* [4].

The major FQ resistance mechanisms found in non-susceptible clinical isolates of *P. aeruginosa* are mutations in the quinolone resistance-determining regions of the genes encoding the FQ-target proteins (*gyrA* and *parC*), and over-expression of specific efflux pumps [6–8]. It has been additionally shown that efflux pump-mediated FQ resistance may also induce a broader, MDR phenotype [7, 8]. However, recent data have questioned the significance of the efflux pump activity in FQ-resistant *P. aeruginosa*. The aim of this study was to investigate the resistance mechanisms that are induced by FQs (and other antimicrobials) in *P. aeruginosa* via prolonged exposure to the FQ, moxifloxacin (MOX).

Materials and Methods

Bacterial strain and MOX exposure in P. aeruginosa

In this study, *P. aeruginosa* ATCC 9027 strain (susceptible to MOX, 1 mg/L) was used as starting strain. This strain was serially exposed to MOX concentrations corresponding to half of the minimum inhibitory concentration (MIC) in Mueller–Hinton Broth (MHB) [9]. Once *P. aeruginosa* ATCC 9027 reached a stable MOX-MIC equilibrium (day 12 of serial exposure), the MOX-resistant strain (designated as MOX-resistant *P. aeruginosa*) was sub-cultured repeatedly onto medium not supplemented with antimicrobials for an additional 12 days in an attempt to obtain a MOX-susceptible strain (designated as MOX-revertant *P. aeruginosa*). The MICs were measured daily. The derived MOX-resistant and MOX-revertant *P. aeruginosa* strains were re-identified as *P. aeruginosa* by standard bacterial identification methods and 16S rRNA sequencing.

Antimicrobial susceptibility testing

The susceptibility test of three bacterial strains (*P. aeruginosa* ATCC 9027, MOX-resistant *P. aeruginosa*, and MOX-revertant *P. aeruginosa*) was determined for nalidixic acid, norfloxacin, ciprofloxacin, levofloxacin, cephalexin, chloramphenicol, lincomycin, erythromycin, and tetracycline using the micro-dilution method in 96-well plates. All tests were performed in duplicate using MHB and

were incubated at 37 °C for 18–24 h. The results were interpreted in accordance with the EUCAST breakpoint tables [10].

Polymerase chain reaction (PCR) amplification and sequencing of FQ-target and efflux regulatory genes

To assess the antibiotic resistance mechanism of the induced, non-reversible, MOX-resistant phenotype, genomic DNA from wild-type *P. aeruginosa* ATCC 9027 and the two MOX-resistant strains (post-12 days' MOX sub-culture and post-12 days' non-supplemented sub-culture) was extracted. These DNA extractions were used as templates to amplify the genes encoding the FQ-target proteins (*gyrA* and *parC*) and efflux regulatory genes (*mexT*, *mexR*, *nalC*, and *nfxB*). Each of PCR reaction contained a volume of 50 µL using TopTaq Master Mix Kit (Qiagen, Hilden, Germany). The amplification conditions are as previously described [6, 8, 11, 12] and the primers are shown in Table I.

Amplification profile of *nfxB* was as follows: 4 min at 94 °C, followed by 30 cycles (1 min at 94 °C, 45s at 49.3 °C, and 2 min at 72 °C) and a final 5 min elongation at 72 °C. The PCR products were finally electrophoresed and subjected to sequencing. The *nfxB* sequence of *P. aeruginosa* ATCC 9027, MOX-resistant *P. aeruginosa*, and MOX-revertant *P. aeruginosa* in this study have been submitted to GenBank under accession nos. KR673324, KR673325, and KR673326.

Reverse transcription-PCR (RT-PCR) analysis

To test the effect of the deletion in the *nfxB* gene, total RNA extraction and cDNA synthesis were performed for *P. aeruginosa* ATCC 9027, MOX-resistant

Table I. List of primers used in this study for PCR and RT-PCR

Gene	Forward (5'→3')	Reverse (5'→3')	Reference
<i>Primers for PCR</i>			
<i>gyrA</i>	GTGTGCTTTATGCCATGAG	GGTTTCCTTTTCCAGGTC	[6]
<i>parC</i>	CATCGTCTACGCCATGAG	AGCAGCACCTCGGAATAG	[6]
<i>mexT</i>	GTAGTAGACGCTGGCCTCCAC	GTGAATTCGTCCTCCACTCGTTC	[7]
<i>mexR</i>	CATTAGGTTTACTCGGCCAAACC	CGCCAGTAAGCGGATACCTG	[11]
<i>nalC</i>	TCAACCCTAACGAGAAACGCT	TCCACCTCACCGAACTGC	[12]
<i>nfxB</i>	CGATCCTTCTATTGCACGC	AGGGTGATGAACAGTTCGGT	This study
<i>Primers for RT-PCR</i>			
<i>mexC</i>	AGCCAGCAGGACTTCGATACC	ACGTCGGCGAACTGCAAC	[13]
<i>rpsL</i>	GCAACTATCAACCAGCTGGTG	GCTGTGCTCTTGCAGGTTGTG	[13]
<i>oprJ</i>	GTTCCGGGCCTGAATGCCGCTGC	TCGCGGCTGACCAGGGTCTGACG	[14]

P. aeruginosa strain, and MOX-revertant *P. aeruginosa* strain. RT-PCR was performed to determine the expression of *mexC* and *oprJ*. All of the reagents for these experiments were purchased from Qiagen. The amplification profile of RT-PCR included denaturation at 95 °C for 5 min and followed by 40-cycle steps, including denaturation for 30 s at 95 °C, annealing for 30 s at 55 °C, elongation for 30 s at 72 °C, and a final elongation at 72 °C for 10 min. *rpsL* was used as an internal control in all RT-PCR experiments [13]. The band intensities were quantified in relation to the *rpsL* band using ImageJ software (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA).

Results and Discussion

Serial exposure of P. aeruginosa to MOX

In this study, over the period of sub-culture, there was a sequential increase in MIC against MOX. After 12 days, a MOX-resistant *P. aeruginosa* was derived and had plateaued at an MIC of 128 mg/L; wild-type MIC 1 mg/L (Figure 1). Notably, our attempt to derive a MOX-susceptible revertant strain was unsuccessful, as the MOX-resistant *P. aeruginosa* did not revert to a susceptible phenotype despite 12 days of sub-culture in non-supplemented growth media.

Susceptibility of P. aeruginosa strains

With regard to susceptibility tests, we observed a significant increase in MIC between the wild-type and the MOX-resistant isolate against all antimicrobials:




Figure 1. MOX exposure to *P. aeruginosa* ATCC 9027 strain. *P. aeruginosa* ATCC 9027 was exposed to MOX for 12 days to obtain MOX-resistant *P. aeruginosa*. This strain was continuously sub-cultured for another 12 days in antibiotic-free medium with daily examination of MIC (MOX-revertant strain)

nalidixic acid (16→128 mg/L), norfloxacin (0.125→16 and 8 mg/L for MOX-resistant and MOX-revertant strains), ciprofloxacin (0.0625→8 mg/L), levofloxacin (0.25→8 mg/L), cephalexin (2→16 mg/L), chloramphenicol (2→16 mg/L), lincomycin (1→4 mg/L), erythromycin (2→8 mg/L), and tetracycline (1→32 mg/L). Notably, there was no difference between the MICs in the primary MOX-resistant isolate and the secondary MOX-resistant isolate (MOX-revertant strain) after 12 days on non-selective growth media.

These data indicated that after being exposed to MOX, susceptible *P. aeruginosa* strain could turn into multidrug-resistant phenotype not only to other FQs but also to other antibiotics of unrelated groups.

Sequencing results of gyrA, parC, mexT, mexR, nalC, and nfxB

The most common and extensively studied mechanism of FQ resistance is the alteration of the FQ targets resulting from mutation in one or more of the genes encoding for gyrase and topoisomerase IV [15]. These enzymes are both tetrameric with pairs of two different sub-units: GyrA and GyrB for gyrase and ParC and ParE for topoisomerase IV. The genes encoding for these sub-units are chromosomally encoded and named *gyrA*, *gyrB*, *parC*, and *parE*, respectively. Until recently, the acquisition of FQ resistance in *P. aeruginosa* is known to be mainly due to the mutations in target genes, *gyrA* and *parC* [6]. However, after successful amplification and DNA sequencing of amplicons, we found that neither of the novel strains contained mutations in *gyrA* and *parC* in comparison with wild-type *P. aeruginosa* ATCC 9027.

The phenomenon of enhanced expression of endogenous efflux systems that restrict the accumulation of drugs inside bacterial cell is well described in *P. aeruginosa* [16]. It is common that organisms with enhanced efflux activity have an MDR phenotype [17]. In FQ-resistant *P. aeruginosa*, mutations are often found in regulators that can have a dramatic effect on drug efflux pump activity [7, 8]. To test this efflux pump activity hypothesis, we amplified the genes *mexT*, *mexR*, *nalC*, and *nfxB* in the three strains and sequenced the resulting amplicons. No modifications indicative of changed regulation in *mexT*, *mexR*, or *nalC* have been found.

Point mutations in *nfxB* were frequently found in clinical *P. aeruginosa* isolates and involved in the reduction of the susceptibility to FQs, especially for ciprofloxacin [18–20]. In this study, we identified a 100-bp deletion in *nfxB* genes in the MOX-resistant and MOX-revertant strains from nucleotide position 196→296 (GenBank accession no. KR673324). This seemed strongly related to a high level of MOX resistance as no significant mutations on principal genes involving in drug resistance were found. This finding supported Monti et al.'s [21]

study which showed that *nfxB* mutations including substitution, 1-bp deletion and insertion, >1-bp deletion, and duplication mutations were also linked to FQ (ciprofloxacin) resistance in *P. aeruginosa*.

Disruption of nfxB resulting in elevated expression of multidrug efflux pumps

nfxB is a repressor of *mexCD-oprJ* a multidrug efflux operon of *P. aeruginosa* [22, 23]. Loss of function mutations in *nfxB* is typically associated with an over-expression of *mexCD-oprJ* [9, 24]. However, occurrence of *mexCD-oprJ*-expressing mutants was very rare in a clinical setting [20, 25, 26]. To assess whether the 100 bp within *nfxB* was influencing *mexCD-oprJ* expression, we determined the expression of *mexC* and *oprJ* by RT-PCR. As predicted, the *nfxB* deletion in the MOX-resistant and MOX-revertant *P. aeruginosa* strains induced an increase in expression of both *mexC* and *oprJ* (Figure 2).




Figure 2. Comparison of *mexC* and *oprJ* expression between initial *P. aeruginosa* ATCC 9027 and MOX-exposed strains. Expression of *mexC* (A) and *oprJ* (B) was assessed in initial *P. aeruginosa* (1), MOX-resistant *P. aeruginosa* (2), and MOX-revertant *P. aeruginosa* (3). *rpsL* was used as internal control. The band intensities were quantified by ImageJ software

Conclusion

In conclusion, we report that disruption of *nfxB* gene plays an important role in the development of FQ resistance and an MDR phenotype in *P. aeruginosa*. In this study, *P. aeruginosa* can gain resistance to FQs and other antibiotics via mutations in intrinsic regulatory pathways. Furthermore, the type of gene regulation containing this disruption seems not reversible resulting in stable MDR phenotype. The mechanism underlying the resistance to antibiotics of other classes is currently unknown but could be of clinical significance in an era of diminishing antibiotic treatment options for *P. aeruginosa* infection.

Acknowledgements

This research was supported by TWAS under grant number 15-235 RG/BIO/AS_I and International University, VNU-HCMC under grant number SV2013-02-BT.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Mesaros, N., Nordmann, P., Plesiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., Tulkens, P. M., Van Bambeke, F.: *Pseudomonas aeruginosa*: Resistance and therapeutic options at the turn of the new millennium. *Clin Microbiol Infect* **13**, 560–578 (2007).
2. Strateva, T., Yordanov, D.: *Pseudomonas aeruginosa* – A phenomenon of bacterial resistance. *J Med Microbiol* **58**, 1133–1148 (2009).
3. Aldred, K. J., McPherson, S. A., Turnbough C. L., Jr., Kerns, R. J., Osheroff, N.: Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance. *Nucleic Acids Res* **41**, 4628–4639 (2013).
4. Gasink, L. B., Fishman, N. O., Weiner, M. G., Nachamkin, I., Bilker, W. B., Lautenbach, E.: Fluoroquinolone-resistant *Pseudomonas aeruginosa*: Assessment of risk factors and clinical impact. *Am J Med* **119**, 526.e19–526.e25 (2006).
5. Redgrave, L. S., Sutton, S. B., Webber, M. A., Piddock, L. J.: Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. *Trends Microbiol* **22**, 438–445 (2014).

6. Salma, R., Dabboussi, F., Kassaa, I., Khudary, R., Hamze, M.: *gyrA* and *parC* mutations in quinolone-resistant clinical isolates of *Pseudomonas aeruginosa* from Nini Hospital in north Lebanon. *J Infect Chemother* **19**, 77–81 (2013).
7. Tian, Z. X., Mac Aogain, M., O'Connor, H. F., Fargier, E., Mooij, M. J., Adams, C., Wang, Y. P., O'Gara, F.: MexT modulates virulence determinants in *Pseudomonas aeruginosa* independent of the MexEF-OprN efflux pump. *Microb Pathog* **47**, 237–241 (2009).
8. Higgins, P. G., Fluit, A. C., Milatovic, D., Verhoef, J., Schmitz, F. J.: Mutations in *GyrA*, *ParC*, *MexR* and *NfxB* in clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* **21**, 409–413 (2003).
9. Avrain, L., Garvey, M., Mesaros, N., Glupczynski, Y., Mingeot-Leclercq, M. P., Piddock, L. J., Tulkens, P. M., Vanhoof, R., Van Bambeke, F.: Selection of quinolone resistance in *Streptococcus pneumoniae* exposed *in vitro* to subinhibitory drug concentrations. *J Antimicrob Chemother* **60**, 965–972 (2007).
10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) documents. Document version 5.0, 2015-05-01.
11. Daigle, D. M., Cao, L., Fraud, S., Wilke, M. S., Pacey, A., Klinoski, R., Strynadka, N. C., Dean, C. R., Poole, K.: Protein modulator of multidrug efflux gene expression in *Pseudomonas aeruginosa*. *J Bacteriol* **189**, 5441–5451 (2007).
12. Sadeghifard, N., Valizadeh, A., Zolfaghary, M. R., Maleki, M. H., Maleki, A., Mohebi, R., Ghafourian, S., Khosravi, A.: Relationship between the presence of the *nalC* mutation and multidrug resistance in *Pseudomonas aeruginosa*. *Int J Microbiol* **2012**, 575193 (2012).
13. Morita, Y., Murata, T., Mima, T., Shiota, S., Kuroda, T., Mizushima, T., Gotoh, N., Nishino, T., Tsuchiya, T.: Induction of *mexCD-oprJ* operon for a multidrug efflux pump by disinfectants in wild-type *Pseudomonas aeruginosa* PAO1. *J Antimicrob Chemother* **51**, 991–994 (2003).
14. Dumas, J. L., van Delden, C., Perron, K., Kohler, T.: Analysis of antibiotic resistance gene expression in *Pseudomonas aeruginosa* by quantitative real-time-PCR. *FEMS Microbiol Lett* **254**, 217–225 (2006).
15. Jacoby, G. A.: Mechanisms of resistance to quinolones. *Clin Infect Dis* **41**, S120–S126 (2005).
16. Aeschlimann, J. R.: The role of multidrug efflux pumps in the antibiotic resistance of *Pseudomonas aeruginosa* and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* **23**, 916–924 (2003).
17. Hooper, D. C.: Emerging mechanisms of fluoroquinolone resistance. *Emerg Infect Dis* **7**, 337–341 (2001).
18. Jalal, S., Ciofu, O., Hoiby, N., Gotoh, N., Wretling, B.: Molecular mechanisms of fluoroquinolone resistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* **44**, 710–712 (2000).
19. Henrichfreise, B., Wiegand, I., Pfister, W., Wiedemann, B.: Resistance mechanisms of multiresistant *Pseudomonas aeruginosa* strains from Germany and correlation with hypermutation. *Antimicrob Agents Chemother* **51**, 4062–4070 (2007).
20. Poole, K.: *Pseudomonas aeruginosa*: Resistance to the max. *Front Microbiol* **2**, 65 (2011).
21. Monti, M. R., Morero, N. R., Miguel, V., Argarana, C. E.: *nfxB* as a novel target for analysis of mutation spectra in *Pseudomonas aeruginosa*. *PLoS One* **8**, e66236 (2013).

22. Pursell, A., Poole, K.: Functional characterization of the NfxB repressor of the *mexCD-oprJ* multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiology* **159**, 2058–2073 (2013).
23. Hosaka, M., Gotoh, N., Nishino, T.: Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of *Pseudomonas aeruginosa* and production of a monoclonal antibody specific to OprJ. *Antimicrob Agents Chemother* **39**, 1731–1735 (1995).
24. Jakics, E. B., Iyobe, S., Hirai, K., Fukuda, H., Hashimoto, H.: Occurrence of the *nfxB* type mutation in clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **36**, 2562–2565 (1992).
25. Jeannot, K., Elsen, S., Kohler, T., Attree, I., van Delden, C., Plesiat, P.: Resistance and virulence of *Pseudomonas aeruginosa* clinical strains overproducing the MexCD-OprJ efflux pump. *Antimicrob Agents Chemother* **52**, 2455–2462 (2008).
26. Kiser, T. H., Obritsch, M. D., Jung, R., MacLaren, R., Fish, D. N.: Efflux pump contribution to multidrug resistance in clinical isolates of *Pseudomonas aeruginosa*. *Pharmacotherapy* **30**, 632–638 (2010).